Followers | 2543 |
Posts | 250732 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Tuesday, May 26, 2015 5:51:39 PM
$PMCB (PHARMACYTE BIOTECH INC)
head back into the wild world of the
Medical Marjuana and Biotech Sectors
with a familiar face - PMCB!
PMCB claims to be inching closer to Human Clinical Trials and now trades right above the 50 Day Moving Average support!
Could another big rally be in the works?
http://www.pharmacytebiotech.com/
????? heating ?????/ up again right now - especially with Alaska, Washington DC, and
Oregon joining
Washington and
Colorado to fully legalize recreational use -
PMCB is back at those same support levels it rallied from this Spring!
PMCB is one of the few Biotech companies in the Medical Marjuana sector as it focuses on potentially ground-breaking applications for illnesses such as
Cancer and Diabetes through it's cutting-edge "Live-Cell Encapsulation" Technology to which they claim world-wide exclusive rights.
But what really has us excited is the company's research in Ca.nnabis with this "Cell-in-a-Box" technology!
http://www.Wealthmakers.com, a Wall St. research
profile on PMCB at around .16 initially saw a rocky road before eventually rising to highs of .2615 last month.
PMCB has retreated from April's highs and now sits right above the crucial 50 Day Moving Average (blue line) support at around $0.13
50 Day Average has been trending north, so if the trend holds, we could eventually see a GOLDEN CROSS of the 50 and 200 Day Moving Averages - tremendous Bullish signal!
PMCB - THE NEXT BREAKTHROUGH BIOTECH IN CANCER TREATMENT?
PharmaCyte Biotech (PMCB) is an international clinical stage biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cell technology known as Cell-in-a-Box(R).
The company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating the use of medical marjuana for oncology applications.
how does Cell-in-a-Box Encapsulation work?
This technology employed by PMCB is a way to enclose living cells in a protective "cocoon" about the size of the head of a pin - holding appx. 10,00 cells.
This technology can be classified as a “platform” upon which treatments for different indications may be built.
capsules that enclose cells are made of cellulose, they are very robust, do not degrade, and can withstand various external forces and this allows them to be implanted using needles or catheters without damage.
Combatting Diabetes, Pancreatic & Breast Cancer
PMCB's pancreatic cancer treatment consists of the use of a proprietary cellulose-based live-cell encapsulation technology together with the long-known and widely used anticancer drug ifosfamide (IFEX®).
Ifosfamide is a prodrug that must be activated to its "cancer-killing" form for it to be effective; this usually occurs in the liver.
These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.
Call it "targeted chemotherapy" - which has proven remarkably effective in past clinical trials.
American Cancer Society estimates that in the U.S. alone, 45,220 new cases of pancreatic cancer will be diagnosed in 2013 and 38,460 deaths will be attributable to the dreaded disease this year.
PMCB is currently preparing for future Phase 2b clinical trials with the hopes of also gaining FDA approval of their unique live-cell encapsulation-based treatment for advanced, inoperable pancreatic cancer.
IN MAJOR RECENT NEWS:
PMCB has been quite busy as of late as they move closer to Human Clinical Trials....
Last month they announced that their Melligen Cell Line could potentially reverse diabetes!
PMCB also announced last month that they have added a former Pfizer and Alchemia Executive to their Board!
PMCB announced they have received "orphan drug" designation from the U.S. Food and Drug Administration (FDA) for the Company's pancreatic cancer treatment, with applications filed with the EMA and the TGA for the same status in Europe and Australia!
PMCB also announced key partnerships with Fisher BioServices and Inno Biologics to generate cell clones which are essential to the company's Phase III Trials for encapsulating cells for pancreatic cancer treatments.
How big is this news?
So big that PMCB was featured in a recent FORBES Article highlighting this partnership!
PMCB BELIEVES CANNAB.IS CAN TREAT CANCER VIA CELL-IN-A-BOX
This is one diverse BioTech company!
PMCB is truly taking the idea of "Medical Mariju.ana" to the next level.
Through their subsidiary, Medical Marjuana Sciences, Inc., they believe utilizing cannabinoids from Cannab.is is an effective treatment for some of the deadliest forms of cancer.
The company first announced breaking news regarding a New Study validating their approach.
PMCB has stated that its subsidiary will attempt to use the "Cell-in-a-Box" encapsulation technology in its medical marjuana research to develop treatments for some of the most hard-to-treat cancers.
PMCB is currently waiting on a Schedule 1 license from the DEA in order to conduct research using marijuana.
PMCB truly remains one of the stand-outs in the Sector due to it's Biotech technology. This company is MORE than just a "Medical Marjuana" stock.
////////////////////////////////////////////////////////////
THE BOTTOM LINE
After a Landmark year in 2014 with New US States legalizing for both recreational and medical use and for the first time
*ever* - a new poll indicating that a majority of Americans now favor legalization, big things may be on the horizon in the next year!
/////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////
Recent PMCB News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 10:06:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:28 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/04/2023 08:40:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:01:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/31/2023 09:18:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM